Sun Pharma Advanced Research Company Ltd Q2FY26 – ₹7.86 Cr Sales, ₹76 Cr Loss, -414% OPM: India’s Only Listed R&D House or a Perpetual Science Experiment?
1. At a Glance
Welcome to the strange little world of Sun Pharma Advanced Research Company Ltd (SPARC) — the country’s first listed pure-play pharmaceutical R&D firm that seems to believe profitability is just an optional elective. With a market cap of ₹4,252 crore and a share price of ₹131 (as of Nov 13, 2025), SPARC continues to be India’s most sophisticated money-incineration machine.
The company posted Q2FY26 revenue of ₹7.86 crore, down 39% YoY, and a net loss of ₹76 crore — roughly ₹83 lakh lost every single day this quarter. Its Operating Profit Margin (OPM) is a chilling -414%, and Return on Capital Employed (ROCE) is a mind-bending -298%. If accounting were a horror movie, this would be the jump-scare moment.
Promoters, led by Dilip Shanghvi (of Sun Pharma fame), still hold 65.7%, proving that conviction sometimes looks a lot like stubbornness. The company’s R&D expenses are gigantic compared to its tiny revenue — because in SPARC’s world, “future potential” is the only currency that matters.
2. Introduction
SPARC was spun out of Sun Pharmaceutical Industries Ltd in 2007 to independently focus on drug discovery, innovation, and technology platforms. Over the years, it’s become the kind of company that investors watch not for quarterly numbers, but for the possibility of a scientific miracle.
It’s not a regular pharma stock; it’s more like a pharmaceutical startup trapped in a listed company’s body. Its revenues come from licensing and royalty fees — and sometimes those cheques don’t arrive on schedule.
Unlike typical drug manufacturers who churn out branded generics and mint cash, SPARC burns it — investing hundreds of crores every year in long-gestation R&D projects. The company’s idea of success isn’t immediate profit; it’s a press release that says, “Phase 2 data readout expected next quarter.”
Investors here are not chasing dividends. They’re chasing dopamine. The stock is down 34% in one year, 19% in three years, and 4.8% in five — a steady reminder that drug discovery is not for the faint-hearted or the impatient.
So what exactly is SPARC trying to cure — diseases, or investor optimism? Let’s find out.
3. Business Model – WTF Do They Even Do?
SPARC doesn’t manufacture drugs. It discovers them, tests them, and (if it survives long enough) licenses them out to Big Pharma partners who take them through commercialization.
Think of it as the “Idea Guy” of the pharmaceutical world — it does the early-stage hard work, then lets someone else make the money.
Its revenue model has two key parts:
License Fees / Royalties – for drugs it develops and licenses to other companies.
R&D Services – working with partners like Visiox Pharma, Johns Hopkins University, and others.
In FY23, the company got USFDA approval for Sezaby (phenobarbital sodium injection) and licensed it out. It’s also developing several novel chemical entities (NCEs) like Vodobatinib, SCD-153, and SBO-154, targeting neurological, autoimmune, and oncology disorders.
SPARC employs 350+ scientists across 4 research facilities in Gujarat and Maharashtra. It has poured in ₹840 crore into R&D over FY22 and FY23. And yet, it barely makes enough revenue to pay for a small clinical trial’s snacks.
If pharma R&D were cricket, SPARC is the nightwatchman — sent in to survive, not score.
4. Financials Overview
Metric (₹ Cr)
Q2FY26
Q2FY25
Q1FY26
YoY %
QoQ %
Revenue
7.86
12.9
10.0
-38.9%
-21.4%
EBITDA
-62
-81
-52
+23.4%
-19.2%
PAT
-76
-108
-52
+29.4%
-46.1%
EPS (₹)
-2.34
-3.32
-1.60
+29.5%
-46.3%
Commentary: Even by SPARC standards, this quarter was a masterclass in losing less money than before — a small victory in a company where “less negative” is the new positive. The loss narrowed 29% YoY, but that’s like saying a ship sank slower this time.
At this burn rate, profitability still feels like a Phase 3 dream sequence.
5. Valuation Discussion – Fair Value Range Only
Let’s have some fun with imaginary math.
P/E Ratio: Not meaningful (because EPS = -₹8.28).
EV/EBITDA: EV = ₹4,668 Cr, EBITDA = -₹237 Cr (TTM approx) → EV/EBITDA = Negative. Translation: If EBITDA were pizza dough, SPARC’s is still raw.
DCF (Discounted Cash Flow): Even an Excel sheet would throw an error here. Future cash flows? Negative till FY27 at least.
So the fair value range (educational purposes only) lies somewhere between ₹100–₹150 per share, purely based on R&D asset potential rather than financial ratios.
Disclaimer: This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
Ah, SPARC’s announcements section — a soap opera written in scientific jargon.
Nov 2023: SPARC licensed SCD-153 for alopecia treatment. Because if you’re going to lose money, at least help others keep their hair.
Mar 2024: Submitted IND application for SBO-154 to USFDA — a key oncology molecule.
Apr 2024: Closed the PROSEEK study after interim analysis. Read that again: “closed,” not “completed successfully.”
May 2024: CFO resigned. Again. They appointed a new one immediately, like a revolving-door internship program.
Sep 2024: Another CFO resigned “for career growth.” Translation: “Enough of these losses.”
May 2025: Approved FY25 results showing ₹3,450 crore loss and ₹1,800 crore fundraise.
Nov 2025: Q2FY26 results showed ₹128 crore H1 loss and ₹310 crore borrowings.
This company is more volatile than a test tube full of lithium.
7. Balance Sheet
Metric (₹ Cr)
Mar 2023
Mar 2024
Sep 2025 (Latest)
Total Assets
830
486
320
Net Worth (Equity + Reserves)
512
-161
-349
Borrowings
16
265
417
Other Liabilities
302
284
252
Total Liabilities
830
486
320
Funny Footnotes:
Equity’s gone from ₹512 Cr to -₹349 Cr — that’s not erosion, that’s vaporization.
Borrowings shot up 26× since FY23, because apparently debt is the new R&D capital.
The “Total Assets” shrank like a stressed balloon from ₹830 Cr to ₹320 Cr.
SPARC’s balance sheet now resembles a skeleton of innovation — fragile, underfed, and full of IOUs.
8. Cash Flow – Sab Number Game Hai
₹ Cr
FY23
FY24
FY25
Operating Cash Flow
-69
-429
-362
Investing Cash Flow
-548
+391
+158
Financing Cash Flow
+617
+43
+201
If money were oxygen, SPARC would be in the ICU. The Operating Cash Flow is consistently negative, suggesting that R&D spending keeps eating away any liquidity they raise through equity or debt.
The only reason the company hasn’t collapsed yet is because of promoter funding and warrant conversions (₹703 Cr in FY23). Like a startup with an infinite lifeline, courtesy of the Sun Pharma
